Ad Zone

Share |

Monday, February 15, 2010

bt brinjal

Briefing Paper on Bt Brinjal
What is Bt Brinjal?
Bt Brinjal is a transgenic brinjal created out of inserting a gene [Cry 1Ac] from the soil bacterium Bacillus thuringiensis into Brinjal. The insertion of the gene into the Brinjal cell in young cotyledons has been done through an Agrobacterium-mediated vector, along with other genes like promoters, markers etc. This is said to give the Brinjal plant resistance against lepidopteran insects like the Brinjal Fruit and Shoot Borer (Leucinodes orbonalis) and Fruit Borer (Helicoverpa armigera). It is reported that upon ingestion of the Bt toxin by the insect, there would be disruption of digestive processes, ultimately resulting in the death of the insect.
Bt Brinjal is being developed in India by M/s Mahyco [Maharashtra Hybrid Seeds Company]. Now, the company wants to take up large scale field trials with the permission of the GEAC in 2006-07. The importance of this development can be understood from the fact that no GM Brinjal has been released for an advanced stage of field trials in open conditions anywhere in the world and that this is the first time that GEAC could be giving permission for large scale open trials for a food crop in India – in a country which has repeatedly proven itself incapable of regulating GM technology and has allowed contamination as a routine affair. The proliferation of illegal Bt Cotton in the country is a good testimony to serious irreversible lapses that could happen at the trials stage. Needless to say, a vegetable, more than other food items, goes through very little processing and is directly consumed through cooking and therefore requires great caution in decision-making.
The transformation work on Bt Brinjal started in Year 2000. Biosafety tests like pollen flow studies, acute oral toxicity etc., were taken up along with back-crossing programme from 2002. After two years of greenhouse evaluation, in 2004, multi-locational field trials were conducted in 11 locations with five hybrids [Mahyco’s MHB-4 Bt Brinjal, MHB-9 Bt Brinjal, MHB-10 Bt Brinjal, MHB-80 Bt Brinjal and MHB-99 Bt Brinjal]. This was also the year when ICAR [Indian Council for Agricultural Research] took up trials with the same hybrids under the All India Coordinated Research Project on Vegetable Cultivation in 11 locations. While the ICAR second year trials continued for these five hybrids in 2005, three more new hybrids were assessed by the company [MHB-11 Bt Brinjal, MHB-39 Bt Brinjal and MHB-112 Bt Brinjal] and ICAR in the same year in eleven centres.
Mahyco has sub-licensed the technology, as part of the USAID-supported, Cornell University-led ABSPII project [consortium of public and private sector institutions] to Tamil Nadu Agricultural University (TNAU), The University of Agricultural Sciences, Dharwad and The Indian Institute of Vegetable Research, Varanasi (IIVR). This transfer of technology was apparently free-of-cost, with the public sector institutes allowed to develop, breed and distribute their own Bt Brinjal varieties on a cost-to-cost basis.
In addition to Mahyco, the National Research Center for Biotechnology at the Indian Agricultural Research Institute (IARI) is also experimenting with Bt Brinjal. They developed a Bt eggplant using a Cry1Ab gene that is claimed to control 70 percent of the fruit borer
Bt Brinjal – a Briefing Paper
Centre for Sustainable Agriculture, June 2006 1
attack. This institute had taken up agronomic trials in a controlled environment in 1998/99, 1999/2000, and 2000/2001. In 2003 they were permitted to conduct field trials in five locations - Delhi, Karnal, Pune, Tamil Nadu Agricultural University and the Indian Institute of Horticultural Research. Another company called Bejo Sheetal company, based in Jalna, Maharashtra, is also working on Bt Brinjal.
Brinjal in India
India is the Centre of Origin for Brinjal or Eggplant. Brinjal has been cultivated in India for the last 4000 years or so and has many historical references in various languages. It is grown all over the country, year-round and is one of the most popular vegetables of India. The area under cultivation is estimated to be around 5 lakh hectares. The total production stands at around 82 lakh metric tonnes. It is mainly grown in small plots as a cash crop by farmers. The average yields of Brinjal in India are reported to be around 200 to 350 quintals per hectare. The main growing areas are in the states of Andhra Pradesh, Bihar, Karnataka, Maharashtra, Orissa, Tamil Nadu, Uttar Pradesh and West Bengal.
There are many local varieties in India, in addition to improved varieties and hybrids. Some of the public sector improved varieties include Pusa Kranthi, Pusa Purple Cluster, Syamala etc. Hybrids include Arka Navneet, Pusa Hybrid 6, Utkarsha, Pusa Hybrid 5 etc. from the public sector in addition to private sector hybrids.
It is estimated that the damage caused by the Shoot & Fruit Borer in brinjal [which has been the major pest for the past two decades or so] ranges from 50 to 70% and in economic terms, it is estimated to be around $221 millions. It is to lend tolerance to this pest primarily that the Bt Brinjal has been developed.
The promises and claims
• It is reported that the average shoot damage in Bt Brinjal hybrids ranged from 0.04% to 0.3% as compared to 0.12% to 2.5% in non-Bt Brinjal hybrids.
• The percentage of damaged fruits reportedly ranged from 2.5% to 20% in Bt Brinjal to 24% to 58% in non-Bt counterparts
• No significant difference was noted between Bt Brinjal and Non-Bt Brinjal, as per the company which did biosafety tests like acute oral toxicity, sub-chronic oral toxicity in rats, allergenecity of protein to rats, germination, weediness and aggressiveness tests, soil micro-biota studies etc.
• This will help small and marginal farmers from having to use 25-80 sprays of pesticides which are ineffective, says the company
• The company claims that human health concerns due to pesticide use can be addressed with this transgenic Brinjal with its in-built tolerance
• Company promises that through this in-built tolerance, there would be substantial increase in marketable yields. Higher yields would result in higher incomes for farmers, it is expected
• The pricing of the seeds will be based on a cost-recovery model, making it affordable for all farmers, whether the seed comes from the private sector or the public sector, it is promised
• Farmers will be able to continue to save and re-use their seed for the hybrids and varieties because of this arrangement, it is reported
Bt Brinjal – a Briefing Paper
Centre for Sustainable Agriculture, June 2006 2
The reality
The current reality is that the Indian regulatory regime with regard to GM crops has never been assessed thoroughly as to whether the right questions are being asked with regard to GM risk assessment in Indian conditions. As in other parts of the world, the current safety assessments are inadequate to catch most of the harmful effects from GM crops, that too in an early warning system. It is no longer in question that GM technology is unpredictable and imprecise, that too when released in an open environment situation. Therefore, there are many worrisome issues with regard to this Bt Brinjal too.
Potential Health Hazards
Several studies on Bt crops in particular and GM crops in general show that there are many potential health hazards in foods bio-engineered in this manner. GM-fed animals in various studies have shown that there are problems with growth, organ development and damage, immune responsiveness and so on. With Bt crops, a recent study from Madhya Pradesh in India shows adverse human health impacts in farm and factory workers with allergies caused by Bt Cotton. Itching skin, eruptions on the body, swollen faces etc., were also reported, correlated with levels of exposure to Bt Cotton.
A study from Phillippines shows that people living next to Bt Corn crop fields had developed many mysterious symptoms, especially during pollination time.
It has also been shown from studies elsewhere that genes inserted into GM food survive digestive processes and are transferred into the human body. They are known to have transferred themselves into intestinal bacteria too. Bt toxin had caused powerful immune responses and abnormal cell growth in mice. It has also been shown that all the Cry proteins in Bt crops have amino acid sequence similar to known allergens and are hence potential allergens.
Potential Environmental Hazards [incl. Monoculture of Bt.]
Resistance development in the target pest is predictable and therefore, even the companies promoting Bt Brinjal are already talking about resistance management. They say that a structured refuge of 5% of non-Bt Brinjal is needed as a strategy for resistance management.
There have not been adequate tests done to assess the changes to the farm level ecology or stress intolerance of Bt Brinjal. In the case of Bt Cotton, however, it is now admitted in official records that Bt Cotton is more vulnerable to sucking pests than non-Bt counterparts, that it is more stress intolerant and so on. Disease incidence on Bt Cotton is also seen to be higher than on non-Bt Cotton.
In the case of Bt Cotton, it is only after a few years of commercial cultivation that recommendations related to some changed management practices are being made by the industry and the government. It is obvious that the research phase of the development of the transgenic did not happen long enough or comprehensively enough for such lessons to emerge during the experimentation phase. Experiments then, are happening at the expense of farmers!
Bt Brinjal – a Briefing Paper
Centre for Sustainable Agriculture, June 2006 3
Further, farmers from various parts of the country are reporting a decline in their soil productivity after growing Bt Cotton. While the regulatory tests related to Bt toxin presence and persistence in the case of Bt Cotton showed that the half-life of Cry1Ac protein in plant tissue was calculated at 41 days [which could then persist in the soil as other studies from elsewhere show], it is not clear how in the case of Bt Brinjal it is non-detectable in soil samples tested. Worldwide, it is generally accepted that more studies are needed to understand the impact of Bt toxin on soil ecology.
In the case of pollen flow, it is well known that there is ample opportunity for cross pollination in the case of Brinjal. The rates of natural cross pollination may vary depending on genotype, location, insect activity etc. However, it has been reported that the extent of natural outcrossing is from 2 to 48% in the case of India. Further, it is not clear whether there is enough data on the wild and weedy plants that are either close relatives or have some degree of cross-compatibility with these brinjal varieties. The pollen flow studies on Bt Brinjal in India have been done only in one year [2002, even as the backcrossing programme was on?], in two locations, with reported outcrossing put at 1.46% and 2.7% in these two locations. Such pollen flow studies cannot obviously rely on data from one season and two locations. Studies elsewhere have shown that the likelihood of outcrossing from genetically engineered crops is much higher than in non-engineered crops. For obvious reasons, the same care that is taken for maintaining seed production standards [of 200 metres], has to be applied for the worst case scenario with Bt Brinjal. In such a case, will Bt Brinjal farmers, who are mostly small and marginal farmers, be able to conform to such guidelines?
Let us also consider a scenario where our predominant pest management strategy relies more and more on one gene – the Bt toxin gene, across crops for a range of pests. Such a monoculture of the gene across crops and varieties is bound to spell doom sooner or later.
Other issues
• As already pointed out, the risk assessment in India does not compare the GM alternative with that of other alternatives like IPM/NPM/Organic etc. Further, the socio-economic risk assessment does not ask fundamental questions related to the interests of the poorest and most marginalized farmers.
• Biosafety testing in India does not recognize the need for studying the medium- and long-term impacts of the GM technology. In the absence of such testing, we are only sitting on a potential disaster which would end up in a cocktail situation very soon, where even correlating an effect with a particular cause will become a challenging task.
• No tests were conducted to check for the effect of Bt Brinjal on the crop raised subsequently; similarly, feeding tests did not include open grazing of the animals on Bt Brinjal plants [in the case of Bt Cotton, open grazing is being reported to cause morbidity and mortality in animals]. It is alarming to note that despite several shortcomings pointed out with biosafety testing in the past, almost the same set of tests with same protocols are being conducted with Bt Brinjal as in the case of Bt Cotton without giving the food crop the due importance and diligence it deserves for its potential adverse impacts.
Bt Brinjal – a Briefing Paper
Centre for Sustainable Agriculture, June 2006 4
• Even on the limited number of biosafety tests done, there is no independent safety testing undertaken by the vast public sector research establishment of the country. There is a serious and objectionable conflict of interest in the fact that majority of the tests were undertaken by the company promoting Bt Brinjal [pollen flow studies, Cry1Ac protein express, baseline susceptibility, protein estimation in cooked fruits, soil analysis, substantial equivalence studies etc. etc.]. Out of the various tests conducted, only 4 were conducted by public sector institutions.
• With the promotion of GM agriculture in general and with Bt Brinjal in this case, the rights of non-GM farmers to stay GM-free get badly affected. This is because segregation and co-existence is impossible in this country.
• While the companies are promising a pricing policy based on a cost-recovery principle, it has to be noted that such cost-recovery itself would be much higher than other seed accessible to farmers as of now. This involves both direct costs of research as well as indirect costs of aggressive promotion and PR that the companies would indulge in. The past history of MMB in the case of Bt Cotton shows that the company will go to the Courts if required to secure its rights related to pricing. Therefore, it is difficult to believe the promises on pricing.
• In the past, several biosafety violations and unscientificities in trials were investigated by civil society organizations, including on Bt Brinjal. However, the Indian regulatory system showed its incompetency yet again by not fixing any liability on the violators and by not strengthening its research regulation regime to this day. Even though biosafety of the product was not cleared, trials were allowed to take place in farmers’ fields with no monitoring mechanism from the side of the GEAC and the state governments concerned.
• There have been no independent tests conducted by the Ministry of Health, considering that this is an important food crop in the country. The entire approval process in the country is being pushed at high speed by the Department of Biotechnology, some bilateral agencies like the USAID and the private biotech industry. This is unacceptable since the primary stakeholders like farmers and consumers and some Ministries like Health are not being involved in these decision-making processes.
Are there no alternatives to Bt Brinjal?
The Bt Brinjal field trials have been compared with their non-Bt counterparts and some national checks to understand the benefits that might potentially accrue to the farmers. They have not been compared to other safer, inexpensive alternatives, however.
There is a lot of experience in mechanical control as well as non-chemical IPM strategies within the Indian research system. Further, there is much experience of non-chemical brinjal cultivation in farmers’ fields by many practicing organic and NPM farmers in the country. Simple things like pheromone traps for mass trapping, sanitation of the field [timely removal and destruction of affected shoots & fruits], mechanical barriers, use of some local plant extracts for pest control etc., have all worked well for farmers. However, the evaluation of Bt Brinjal is not taking place against such options as part of the Risk Assessment.
Given below is tabulated information from the ICAR-supervised, Mahyco-commissioned multilocational trials in their second year [2005-06] for five hybrids and in their first year for
Bt Brinjal – a Briefing Paper
Centre for Sustainable Agriculture, June 2006 5
Bt Brinjal – a Briefing Paper
Centre for Sustainable Agriculture, June 2006 6
3 other hybrids, compared with their non-Bt counterparts and with some popular checks. The table also has comparative figures from experiences with IPM packages applied in some locations.
Bt Brinjal (mean of Mahyco hybrids from 8 locations) – 2005-06
Non-Bt counterparts (mean of non-Bt counterpart hybrids from 8 locations)
Two checks (mean of Pusa Hybrid 6 and Navkiran)
IPM by GAU* (two locations in farmers’ fields) – 2001
IPM by ANGRAU** (at VRS, Hyderabad) 2000-02)
Non-Chemical IPM by OUAT*** (farmers’ fields) – Summer 2004
13.5% (5 hybrids in Year II)
28.7% (5 hybrids in Year II)
29.4% (5 hybrids in Year II)
(Cumulative) Fruit Damage
16.02 (3 hybrids in Year I)
27.72% (3 hybrids in Year I)
27.69% (3 hybrids in Year I)
10.64%
17.72%
13.07+/-7.54
231.69 q/ha (5 hybrids in Year II)
157.08 q/ha (5 hybrids in Year II)
182.15 q/ha (5 hybrids in Year II)
Marketable yield
223.39 q/ha (3 hybrids in Year II)
190.36 q/ha (3 hybrids in Year II)
192.86 q/ha (3 hybrids in Year II)
266.25 q/ha
203.98 q/ha
214.5+/-16.3 q/ha
* Technical Bulletin 28 – “Development of an IPM strategy for EFSB in South Asia” – AVRDC, 2003
** Treatment 1 – NSKE-Profenofos-Cypermethrin, on Bhagyamathi brinjal, as reported by Chiranjeevi et al (2005)
*** Dept. of Entomology, College of Agriculture, OUAT, Rath & Dash (2005)
It has to be noted that the data presented by ICAR on Bt Brinjal was not statistically analysed. For instance, the yields across hybrids in the Hyderabad test centre were only 12.04 quintals per hectare. However, the average marketable yield from all locations (231.69 q/ha) conceals this figure. From six centres, the yields were lower than this average, which got skewed by high yield reported from one centre. Similar are dangerous conclusions that can be drawn with data on disease incidence if such conclusions are based on the mean figures being presented. It is also interesting to note that in the ICAR trials, in the case of all the 8 hybrids of Bt Brinjal, their mean fruit weight is far lower than their checks.
As the above table shows and as practicing NPM and organic farmers from various parts of the country would testify, pest management in Brinjal does not need either pesticides or GM seeds when safer, cheaper alternatives in the control of farmers are available.
What is needed is a public support system for such alternatives to be promoted, spread and practiced. Such alternatives inevitably show that the farmers benefit out of increased net incomes, derived from internalizing various inputs including Seed.
References:
• Development of Fruit & Shoot Borer Tolerant Brinjal, paper presented to GEAC on May 22, 2006 by M/S Mahyco
• XXIV All India Coordinated Research Project (VC) Annual Report 2005-06, pp 164-174, 2006
• Rath LK and Dash B, “Evaluation of a Non-Chemical IPM Module for the Management of Brinjal Shoot & Fruit Borer”, Veg. Sci.32(2): 207-209, 2005
• Chiranjeevi CH, Narayanamma M and Neeraja G, “Evaluation of IPM Module for the management of Brinjal Shoot & Fruit Borer”, Veg. Sci. 32(1): 105-106, 2005
• ABSPII – USAID and Cornell University, “Fruit and Shoot Borer-Resistant Eggplant-Fact Sheet”, 2005
• Gupta, Ashish et al, “Impact of Bt Cotton on Farmers’ Health”, Investigation Report, 2005
• “Background Note on Bt Cotton cultivation in India”, MoEF website, Government of India, 2002
• “Development of an IPM strategy for Eggplant Fruit & Shoot Borer in South Asia”, Technical Bulletin 28, AVRDC, 2003

Thursday, January 28, 2010

Molecular Biology/Genomics SRF Opening-NIPGR-Delhi

Posted: 28 Jan 2010 08:18 AM PST

Senior Research Fellow jobs, National Institute of Plant Genome Research Delhi

Designation: Senior Research Fellow (SRF)

Applications are invited from suitable candidates for filling up one position of Senior Research Fellow (SRF) in the DBT:

Project Entitled:
‘Analysis of chickpea response to Ascochyta infection and generation of ORFeome for target genes’

Main Project Entitled: “Next Generation Challenge Programme on Chickpea Genomics”.

Note: The above mentioned position is completely on temporary basis and is co-terminus with the project. The initial appointment will be for a period of one year, but can be curtailed or extended based on the performance of the candidate and discretion of the Competent Authority.

Emoluments: Rs. 14,000/- p.m. + HRA.

Qualifications: M.Sc. (Biotechnology, Molecular Biology, Biochemistry, Botany, Zoology and any other related field)

Experience: Two years post-M.Sc. research experience are eligible to apply. Research experience in Molecular Biology and related
field will be given preference.

*NIPGR may select candidate against the above post depending upon the qualifications and experience of the candidate and reserves
the right to relax any of the qualification(s) in case the candidate is found otherwise well qualified by the Selection Committee.

How To Apply: Interested candidates may apply by sending a cover letter detailing experience, CV, and names with complete address (including e-mail) of three references to the following address latest by February 5, 2010:

Contact: Dr. Praveen Verma
Scientist
National Institute of Plant Genome Research
Post Box No. 10531, Aruna Asaf Ali Marg,
New Delhi – 110 067

E-mail: praveen_verma@nipgr.res.in

Tel. No. 26735114

Source: http://www.nipgr.res.in/employment/advt_220110.html

Project Assistant Vacancy-IICB-Kolkata

Posted: 28 Jan 2010 08:31 AM PST

Project Assistant Vacancy on phytoceuticals, Indian Institute of Chemical Biology Kolkata

Position: Project Assistant Level – II

No. of Vacancies: 1

Walk-in Interview on: 03/02/2010

Time of Interview: From 3.00 PM

Venue: Conference/Red Carpet Room

Name of the Project : Pathway engineering and system biology approach towards homologous and heterologous expression of high-value phytoceuticals.

Sponsor of the Project: CSIR

Name of the PI/Co-PI: Dr. S. Chattopadhyay

Qualification required:
1st Class M.Sc in Biological Science.

Desirable Experience: Experience in plant/Agril Science, like project work / Summer training etc.

Age Limit: 28 Years

Stipend: Rs.10,000/- p.m. (Consolidated)

Terms & Conditions: The engagement is purely temporary and, therefore, does not confer any right / claim implicit or explicit for regularization or absorption against any IICB / CSIR post. The age and qualifications will be reckoned as on the last date of receipt of applications. The upper age limit is relaxable for SC / ST / OBC / PH and women candidates as per rules. Interested candidates fulfilling all the above conditions may appear for the walk-in-interview to be held on 03-02-2010 from 3.00 PM in the Conference/Red Carpet Room.

Adress:
Indian Institute of Chemical Biology (IICB)
4, Raja S.C. Mullick Road Kolkata-700 032

Source: http://www.career.iicb.res.in/Recruitment%20Notice.php

list of bioinformayics companies

From A to H Form I to Z
www-3.ibm.com
www.3rdmill.com
www.4-sci.com
www.GenomicTechnologies.com
www.PharmaDM.com
www.abergc.com
www.aborygen.com
www.accelrys.com
www.acdlabs.com
www.acero.com
www.aclara.com
www.advancedcell.com
www.affymetrix.com
www.agencourt.com
www.agilebio.com
www.agrogene.com
www.algan.com
www.algonomics.com
www.allometra.com
www.almabioinfo.com
www.alphadna.com
www.amartus.com
www.amaxa.com
www.amebioscience.com
www.amita.com
www.ananomouse.com
www.anedabio.com
www.antivirals.com
www.apocom.com
www.applied-maths.com
www.appliedbiosystems.com
www.aptagen.com
www.ariadnegenomics.com
www.arraygenetics.com
www.artificial-life.com
www.atglabsinc.com
www.autohandle.com
www.axontologic.com
www.base4.com
www.benitec.com.au
www.bforrester.com
www.bio-link.org
www.bioalma.com
www.bioanalyticsgroup.com
www.biobase.de
www.biocarta.com
www.biochipnet.com
www.bioclon.com
www.biodata.ee
www.biodatabases.com
www.biodiscovery.com
www.bioforensics.com
www.biognostik.com
www.bioinformaticist.biz
www.bioinformatics.co.uk
www.bioinformatics.csiro.au
www.bioinformaticsservices.com
www.bioinformaticssolutions.com
www.bioinformatik.de
www.bioit-il.com
www.biolateral.com.au
www.biomax.com
www.biomax.de
www.biomedcomp.com
www.biomind.com
www.bioplanet.com
www.biosentients.com
www.biosiris.com
www.biosis.org
www.biosoft.com
www.biosoftsolutions.de
www.biosolve.de
www.biospec.com
www.biotiquesystems.com
www.biotools.com
www.biowell.com.tw
www.biowisdom.com
www.bioxtal.com
www.bluespeed.net
www.bmi-heidelberg.com
www.caesar.de
www.caesarsoftware.com
www.cambridgeantibody.com
www.cambridgebluegnome.com
www.cbssci.com
www.celera.com
www.cellectis.com
www.centagenetix.com
www.ceuticalsoft.com
www.cgen.com
www.changbioscience.com
www.chemcomp.com
www.chemgenes.com
www.cimsoft.com
www.clcbio.com
www.clearlinetech.com
www.clonaid.com
www.clondiag.com
www.cmrsinc.com
www.cognia.com
www.colnow.com
www.compass.com.ph
www.compassgenomics.com
www.compudrug.com
www.compugen.co.il
www.concurrentpharma.com
www.corelims.com
www.corimbia.com
www.correlogic.com
www.cresset-bmd.com
www.crti.com
www.cybergene.se
www.cybgen.com
www.d-trends.com
www.davissequencing.com
www.decode.com
www.decodon.com
www.definiens.com
www.deltagen.com
www.deosystems.com
www.designergenesinc.com
www.discoverypartners.com
www.dna-software.com
www.dna.com
www.dnastar.com
www.dnatools.com
www.doubletwist.com
www.duii.com
www.dxsgenotyping.com
www.dynacom.co.jp
www.e-proteomics.net
www.egenetics.com
www.eidogen.com
www.elitra.com
www.elixirpharm.com
www.employstrat.com
www.entelos.com
www.epigenomics.com
www.epistasis.org
www.epitope-informatics.com
www.eragen.com
www.esearchinternational.net
www.essentialinformatics.com
www.etexxbio.com
www.evprecruit.com
www.expasy.ch
www.eyesopen.com
www.familytreedna.com
www.fqspl.com.pl
www.fractalgenomics.com
www.functional-genetics.com
www.gemini-genomics.com
www.genStruct.com
www.genaissance.com
www.genamics.com
www.gene-alliance.com
www.gene-biotech.com
www.gene-chips.com
www.gene-it.com
www.gene-quantification.de
www.gene2drug.com
www.geneart.com
www.genebio.com
www.geneco.com
www.genecodes.com
www.genedata.com
www.geneformatics.com
www.genego.com
www.genelink.com
www.genelogic.com
www.genemachines.com
www.genepilot.com
www.genesearch.com.au
www.genesifter.net
www.genestudio.com
www.genesynthesis.org
www.genetargeting.com
www.genetherapysystems.com
www.genetic-id-services.com
www.geneticXchange.com
www.geneticxchange.com
www.genetix.com
www.genfit.com
www.genmatrix.com
www.genodyssee.com
www.genologics.com
www.genolyze.com
www.genomatica.com
www.genomatix.com
www.genomatix.de
www.genometrician.com
www.genomica.com
www.genomicdiscoverytools.com
www.genomicsinc.com
www.genomicsolutions.com
www.genomictechnologies.com
www.genomining.com
www.genomix.com
www.genops.com
www.genoptix.com
www.genset.fr
www.gentech.fr
www.geospiza.com
www.glycominds.com
www.gnsbiotech.com
www.goldenhelix.com
www.gtc-bio.com
www.helixinfosystems.com
www.hessjobs.com
www.hippron.com
www.hybridon.com
www.ibiomatics.com
www.idrtech.com
www.idtdna.com
www.illumina.com
www.imagingresearch.com
www.imaxia.com
www.imphasis.com
www.incellico.com
www.incogen.com
www.incyte.com
www.informagen.com
www.informaxinc.com
www.inforsense.com
www.ingenovis.com
www.ingenuity.com
www.innaphase.com
www.innomedical.com
www.inpharmatica.co.uk
www.inpharmatica.com
www.inpharmix.com
www.insightful.com
www.insilico-biotechnology.com
www.insilico.com
www.insilicolabs.com
www.insilicos.com
www.interactiva.de
www.intronn.com
www.inveniobio.com
www.invitrogen.com
www.io-informatics.com
www.iobion.com
www.iper1.com
www.it-omics.com
www.iuvita.com
www.jaexecutivesearch.com
www.jubilantbiosys.com
www.katonahgroup.com
www.kennatechnologies.com
www.kerberholtdevol.com
www.kinematik.com
www.knowledge.com
www.koada.com
www.kooprime.com
www.labbook.com
www.labdb.com
www.lablogic.com
www.labonweb.com
www.labvantage.com
www.lambdaplus.com
www.lazaron.com
www.lifesciencesworld.com
www.lionbioscience.com
www.lloydstaffing.com
www.lsbio.com
www.ludesi.com
www.lynxgen.com
www.macrogen.com
www.mag.com
www.mantik.de
www.markergene.com
www.mastl.com
www.mathecology.com
www.matrixscience.com
www.mdli.com
www.medbioworld.com
www.medicel.com
www.medigenomix.de
www.mendelbio.com
www.meta-helix.com
www.metabolic-explorer.com
www.metalife.de
www.metaphorics.com
www.microdiscovery.de
www.microrite.com
www.midilabs.com
www.miraibio.com
www.mirusbio.com
www.mol-net.de
www.molecularconnections.com
www.molecularmed.com
www.molecularmining.com
www.molecularware.com
www.molmine.com
www.molsoft.com
www.mpi-softtech.com
www.mri-boston.com
www.mutransposon.org
www.mutransposon.orgwww.worksinc.com
www.myriad.com
www.nadii.com
www.neomorphic.com
www.netgenics.com
www.netid.com
www.newportsearch.com
www.nonlinear.com
www.nuvelo.com
www.ocimumbio.com
www.od260.com
www.ogs.com
www.oligos.com
www.omnigon.com
www.omniviz.com
www.ontrackpro.com
www.origenel.com
www.ozgene.com
www.packardbiochip.com
www.pangenex.com
www.paracel.com
www.partek.com
www.peoplesgenetics.com
www.petagen.com
www.ppl-therapeutics.com
www.predictivepatterns.com
www.premierbiosoft.com
www.primegenbiotech.com
www.proceryon.com
www.proconverse.com
www.progeny2000.com
www.proglab.se
www.prolume.com
www.prosanos.com
www.proteinmechanics.com
www.proteom.com
www.proteomeconsult.com
www.proteomes.co.kr
www.pubgene.com
www.puretechventures.com
www.q-pharm.com
www.qgene.com
www.quantiom.de
www.rabbithutch.com
www.receptorscience.com
www.redasoft.com
www.redstormscientific.com
www.reeltwo.com
www.relevantsoftware.com
www.rescentris.com
www.rii.com
www.rosettabio.com
www.sas.com
www.savingsandclone.com
www.science-factory.com
www.scinovaindia.com
www.scitechint.com
www.scitegic.com
www.sdc.co.jp
www.searchfirm.com
www.seascapelearning.com
www.seattlegenetics.com
www.semantxls.com
www.seqbio.com
www.sequenom.com
www.sequiturinc.com
www.seqwright.com
www.sgi.com
www.sgxpharma.com
www.sigenetics.com
www.silicoinsights.com
www.silicongenetics.com
www.simulations-plus.com
www.softberry.com
www.softgenetics.com
www.soonersci.com
www.spotfire.com
www.spsoft.com
www.spss.com
www.sratemecula.com
www.stafftopia.com
www.starbridgesystems.com
www.stewartgroup.net
www.strandgenomics.com
www.strubix.com
www.sunflaremarketing.com
www.synamatix.com
www.syngene.com
www.syngentabiotech.com
www.teranode.com
www.textco.com
www.the-genetics.com
www.tib-molbiol.com
www.timelogic.com
www.tmdg.com
www.transgene.fr
www.transgenic-software.com
www.tripos.com
www.turbogenomics.com
www.ubi.ca
www.valentis.com
www.vglab.com
www.vialogy.com
www.virtualchemistry.com
www.visgen.com
www.visipoint.fi
www.visualizeinc.com
www.vizxlabs.com
www.wabansoftware.com
www.webgenetics.com
www.wireworkswest.com
www.wita-proteomics.com
www.x-mine.com
www.xenogen.com
www.xpogen.com
M I B S I T B T

BIOTECH COMPANIES IN INDIA

BIOTECH COMPANIES IN INDIA

List of Biotech company Click Here

List of Bioinformatics company Click Here

Company Name : Alembic Limited

Address A. P. & M. P. Division Alembic Road Vadodara - 390 003

Phone 0265-280550 / 880

Fax 0265-282931

URL www.alembic-india.co.in

Company Name : All India Biotech Association (AIBA)

Address "VIPSS Centre", 2, Local Shopping Centre, Block EFGH, Masjid

Moth, Greater Kailash-II, New Delhi - 110 048

Phone 011-6430546 / 0446

Fax 011-6469166

URL www.aibaonline.com and www.biotech-int.com

Company Name : Amersham Pharmacia Biotech Asia Pacific Ltd.

Address FF3, First Floor, Palani Center, 32, Venkatanarayan Road, T. Nagar,

Chennai - 600 017

Phone 044-434 0747

Fax 044 4323770

URL www.apbindia.com

Company Name : Aristo Pharmaceuticals Ltd.

Address 23-A, Shah Industrial Estate, Off Veera Desai Road, Andheri (W),

Mumbai - 400 053

Phone 022-6313619, 6313663, 6301326, 6336229

Fax 022-6313695

URL www.aristopharma.com

Company Name : Biotech Consortium India Limited

Address 5th Floor, Anuvrat Bhavan, 210, Deen Dayal Upadhyay Marg, New

Delhi - 110 002

Phone 011-3219064-67

Fax 011-3219063

URL www.biotech.co.in

Company Name : Biotech Equity Research Group

Address Sonawala Building, 2nd Floor, 25, bank Street Fort, Mumbai - 400023

Phone 022-2654676, 2665323

URL www.biotech.equitysearchcentre.com

Company Name : BrainWave Bioinformatics Ltd.

Address MAC House, 4 Sardar Patel Road, Guindy, Chennai -32

Phone 91 44 2220 0890

Fax 91 44 0230 0194

URL www.brainwave.co.in

Company Name : Catalyst Pharma Consulting

Address 71, Dharam Jyot, A. B. Nair Road, Juhu, Mumbai - 400 049

Phone 022-6201018, 6244552

Fax 022-6202248

URL www.CatalystPharmaConsult.com

Company Name : Chaitanya Healthcare Ecom Ltd.

Address Biomix Network Ltd., Millennium Business Park, Unit 303, Bldg. 6,

Sector III, MIDC, Mahape, New Bombay - 400 709

Phone 022-7781108, 7781110 Fax 022-7781110

Company Name : Chemitech Foundation

Address 26, Maker Chambers VI, Nariman Point, Nariman Point, Mumbai - 400 021

Phone 022-2874758 / 59, 2851734 / 74

Fax 022-2870502

URL www.chemtechfoundation.org

Company Name : Colour-Chem Limited

Address Life Science & Electronic Chemicals Divisiion, Mumbai - Agra

Road, Balkum, Thane - 400 608

Phone 022-5345060, 5412479

Fax 022-5345949

URL www.clour-chem.com

Company Name : Diagnostic Systems Laboratories Inc.

Address 144, Udyog Bhavan, Sonavala Road, Goregaon (EAST), Mumbai -

400 063

Phone 022-8716318

Fax 022-8717380

URL www.DSLabs-IN.com

Company Name : Dr. Reddy's Laboratories Ltd.

Address 7-1-27, Ameerpet, Hyderabad - 500 016

Phone 040-3731946 / 1958

Fax 040-3731995 / 9666

URL www.drreddys.com

Company Name : Dr. Sastri's Phytolabs

Address 25, Sri Venkateswara Colony , Lothkunta, Secunderabad - 500 015

Phone 7866625

Company Name : Excel Industries Limited

Address Environ-Biotech Division, Amboli Hill, Veera Desai Road, Andheri

(West), Mumbai

Phone 022-6367697 / 98, 6316100

Fax 022-6310916

URL www.excelind.com

Company Name : Fermenta Biotech Ltd.

Address Opp. Vidyapeeth, S. V. Road, Majiwada, Thane (W)

Phone 022-5341693

Fax 022-5340901

Company Name : Frost & Sullivan

Address Industry Manager - Healthcare Practice, 5, Chunawala Estate,

Kondivitta Road, Andheri (E), Mumbai - 400 059

Phone 022-8324705

Fax 022-8324713

URL www.frost.com

Company Name : Genhelic Bioinformatics Pvt. Ltd.

Address 8-2-541/m/b/2, Road No. 7, Banjara Hills, Hyderabad - 500 034

Phone 040-3358288, 6515655, 6512772

Fax 040-3357958

Company Name : Hi Tech Bio Laboratories

Address Survey No. 36/1/1, M. N. 199, Vadgaon Khurd, Pune - 411 041

Phone 020-4390419 / 4390977

Fax 020-4390978

URL www.htblindia.com

Company Name : International Centre for Genetic and Biotechnology

Address ICGEB Campus, P.O.Box: 10504, Aruna Asaf Ali Marg,

New Delhi -110 067

Phone 011-6102317, 6189360

Fax 011-6162316

URL www.icgeb.res.in

Company Name : Jindal Solvent Extractions

Address Ramnagar Road, Kashipur - 244713, Udham Singh Nagar-

Distt (Uttaranchal)

Phone 05947-78031, 78724

Fax 05947-75372

Company Name : Landpower Biotech Ltd.

Address 29 / 242, Ist Floor, Srinivasa Nagar (West),

Hyderabad - 500 038

Phone 040-3731899, 6508467

Fax 040-3731899

Company Name : Life Science Technology

Address Alfa Laval (India) Limited, Mumbai - Pune Road,

Dapodi, Pune - 411012

Phone 020-7107347, 4116347

Fax 020-7149113

URL http://www.bangalorebio.com/externalsite?http://www.alfalaval.com

Company Name : Lupin Limited

Address 159, C. S. T. Road, Kalina Santacruz (East), Mumbai - 400 098

Phone 022-6931001 , 6526391 / 6575 / 8350

Fax 022-6526092

Company Name : Malladi Research Center

Address 52, Jawaharlal Nehru Road, Guindy, Chennai - 600 097

Phone 2345881

Fax 2345884

Company Name : Nicholas Piramal India Limited

Address 100, Centre Point, Dr. Ambedkar Road, Parel, Mumbai - 400 012

Phone 022-4134653 Extn. 1620

Fax 022-4163787

URL www.nicholaspiramal.com

Company Name : Ocimum Biosolutions Ltd.

Address 404, Reliance Classic, Road No. 1, Banjara Hills,

Hyderabad - 500034

Phone 040-6627200

Fax 040-6627205

URL www.ocimumbio.com

Company Name : Periyar Chemicals Limited

Address Industrial Assurance Building, Churchgate, Mumbai - 400 020

Phone 022-2820663

Fax 022-2811751

Company Name : Scigenics (India) Pvt. Ltd.

Address 18, Vasudevapuram, Triplicane, Chennai - 600 005

Phone 044-4928867 / 4929652

Fax 044-4928880 / 4929652

URL www.scigenics.com.

Company Name : Serum Institute of India

Address 212/2 Hadapsar Pune 411028

Phone 020-269993900

Fax 020-26993921

URL www.seruminstitute.com

Company Name : Shantha Biotechnics Pvt. Ltd.

Address 3rd floor, Serene Chambers Road, No. 7, Banjara Hills,

Hyderabad -500 034

Phone 040-3548507, 040-3543010, 040-3608843

Fax 040-3548476

URL www.shanthabiotech.com

Company Name : Sisco Research Laboratories Pvt. Ltd.

Address 2 / F, Satam Indl. Estate, 'C' Wing, Dr. Cardinal Gracious Road,

Chakala, Andheri (E), Mumbai - 400 099

Phone 022-8203882/ 8214005

Fax 022-8380998

URL www.srlchem.com

Company Name : VARDA Biotech (P) Ltd.

Address # 209, Kartik Complex, New Link Road Andheri ( W),

Mumbai - 400053

Phone 22-5693 5686 / 2673 0141

Fax 22-5693 5687

URL www.vardabiotech.com

Company Name : Yashraj Biotechnology Ltd.

Address Plot. No. C-232, TTC IND. AREA, MIDC, Navi

Mumbai - 400 705

Phone 022-7686226 / 6285

Fax 022-7686087

URL www.yashraj.com

Friday, December 4, 2009

Fwd: Nature Photonics December issue: Focus on Quantum Optics




         
     
 


Nature Photonics is pleased to announce that the December 2009 issue has a special focus on quantum optics. The optical world has long been the perfect playground for exploring quantum mechanics. Now, quantum dreams, from communications and teleportation through to computing and metrology are shaping into reality. This Focus provides a glimpse into the tremendous progress that has been made and the remaining challenges for a bright quantum future.

Articles in this focus issue:

Quantum evolution
Editorial

Low uncertainty for an intriguing future
Interview with Anton Zeilinger

A bright future for quantum communications
Commentary by Timothy C. Ralph and Ping K. Lam

Quantum states made to measure
Commentary by Konrad Banaszek, Rafał Demkowicz-Dobrzański and Ian A. Walmsley

Single-photon detectors for optical quantum information applications
Review by Robert H. Hadfield

Photonic quantum technologies
Review by Jeremy L. O'Brien, Akira Furusawa and Jelena Vučković

Optical quantum memory
Review by Alexander I. Lvovsky, Barry C. Sanders and Wolfgang Tittel

To access this focus, freely available through December 2009, please visit:
http://www.nature.com/nphoton/focus/quantumoptics/index.html

Like what you see? Subscribe now
At a cost of £78 / €121 / $152, a personal subscription provides you with 12 print issues and 12 months' online access to Nature Photonics.

Japan, Korea or China subscriptions
For rates in these regions please visit the NPG Nature Asia-Pacific website at www.natureasia.com.

For a journal that combines the best research in optics with a unique mix of articles dedicated to the business and technology side of the industry, choose Nature Photonics.


 
     
 

As a registered user of Nature Publishing Group's Web sites, our database indicates that you have opted-in to receive product information and special offers. If you no longer wish to receive these e-mails or to discontinue all e-mail services from Nature Publishing Group please update your online account.

Modify My Account (You will need to log in to be recognised as a Nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscriptions department

For other enquiries, please contact our customer feedback department

Nature Publishing Group | 75 Varick St Fl 9 | New York | NY 10013-1917 | USA

Nature Publishing Group's offices:
Principal offices: London &#149 New York
Worldwide offices: Basingstoke &#149 Boston &#149 Buenos Aires &#149 Delhi &#149 Hong Kong &#149 Madrid &#149 Melbourne &#149 Munich &#149 Paris &#149 San Francisco &#149 Tokyo &#149 Washington DC

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.

© 2009 Nature Publishing Group, a division of Macmillan Publishers Limited. All rights reserved.

 
     



--
SITBT

Sunday, November 29, 2009

Department of Biotechnology

Dr.B.S. Gowrishankar
Professor & Head
The research and developments in molecular biology, genetic engineering and in emerging technologies have made the field of Biotechnology an important tool for the socio-economic development. Biotechnology, an interdisciplinary area, derives benefits from the advancements made in the fields of Biology, Chemical Engineering, Electronics, Telecommunications, Instrumentation Technology and Material Sciences. Large scale application of Biotechnology in the areas of agriculture, environment, health care, animal science and
industry is expected to increase, attract foreign investment and provide job opportunities in India and abroad in coming years. Due to favorable patent laws, Indian biotech industries have great potential to grow. The Associated Chambers of Commerce and Industry of India (ASSOCHAM) has predicted that the domestic biotechnology sector in India with a CAGR rate of 35.1% will reach $ 5 Billion mark by 2009-10.

Considering the importance of Biotechnology in the socio-economic development, and availability of expertise and well established infrastructure in related engineering disciplines namely, Chemical Engineering (established in 1974 and also having Master degree and PhD programs), Instrumentation and Electronics Engineering (established in 1979) and Computer Science and Engineering (established in 1986), required for creating center of excellence in the field of Biotechnology, SIT at Tumkur, started BE course in Biotechnology in the academic year 2006-2007 with an intake of 30 students. SIT is one of the few Institutes in India having well established related engineering departments and expertise to support Biotechnology. With the support of above departments, department of Biotechnology is set to provide excellent facilities for human resource development, and research and development in the field of Biotechnology including in the newer areas such as biomems, bioelectronics, biosensors, biomaterials and nano- biotechnology.

In order to encourage close interaction, share experience and augment resources, department of Chemical Engineering and department of Biotechnology are housed in a modern spacious building. Biotechnology department is spread over 20,000 square feet of built in area for classrooms, laboratories for course and research work, departmental library, computer room and seminar hall.

Mission

To provide competent, self-reliant trained manpower required to meet the challenges in research and development, and large scale application of Biotechnology in the areas of agriculture, environment, health care and industry for socio – economic development.

Short Range Goals

To develop facilities and infrastructure for providing excellent training in the field of plant, animal, microbial, environmental and food biotechnology.
To provide trained manpower in the field of biotechnology for research and development, scale–up, equipment design, process development and large scale production of products, and bio services.
Long Range Goals

To Establish pilot plants and scale up studies for bio-diesel from Jartopha and other promising vegetables oil.
To Establish the industrial enzymes preperation and utilization unit.

Check out this profile!

Check out this profile!

Thursday, November 26, 2009

Fwd: SciBX: Science-Business eXchange Contents: November 19 2009, Volume 2 / Issue 45




SciBX: Science-Business eXchange

TABLE OF CONTENTS

November 19 2009, Volume 2 / Issue 45

Analysis

Cover Story
Targets and Mechanisms
Tools

The Distillery: Therapeutics

Cancer
Cardiovascular disease
Dermatology
Hematology
Infectious disease
Neurology
Ophthalmic disease
Pulmonary disease
Renal disease

The Distillery: Techniques

Drug platforms
Imaging



recommend to your libraryRecommend to your library
live newsfeedsWeb feed
Content is available online onlyAvailable online only
subscribeSubscribe
SciBX - Ask your librarian to start a trial today!
SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing.

SciBX is now available in full-text, HTML format on the nature.com platform. Recommend SciBX to your library today
For more information visit: www.nature.com/scibx.
 

Analysis

Cover Story

Top

A top-notch inhibitor
Tim Fulmer
doi:10.1038/scibx.2009.1649
The previously intractable Notch pathway looks to be opening as a Harvard team has described a way to specifically inhibit Notch signaling and UCSD researchers have identified a role for NOTCH3 in pulmonary arterial hypertension. Also, Aileron Therapeutics has moved the Harvard technology into preclinical programs for a range of indications beyond cancer.
Full Text | PDF

Targets and Mechanisms

Top

APC mutants for ALS
Lev Osherovich
doi:10.1038/scibx.2009.1650
University of Rochester researchers suggest mutant forms of activated protein C could improve outcomes in ALS, and they point to a possible role of microglia in the etiology of the disease. The results could expand the number of indications addressed by ZZ Biotech's portfolio of APC mutants.
Full Text | PDF

gp130's sensitive side
Lauren Martz
doi:10.1038/scibx.2009.1651
Medical University Innsbruck researchers suggest that inhibiting the gp130 pathway could help manage certain types of pain as well as exert a therapeutic effect in cancer and inflammation. The key will be to block the pathway without disrupting the body's natural immune response.
Full Text | PDF

Tools

Top

Warming up to lung transplants
Kai-Jye Lou
doi:10.1038/scibx.2009.1652
University of Toronto researchers have combined ex vivo IL-10 gene therapy with an organ preservation system from Vitrolife AB to repair damage in donor lungs and make them suitable for transplant. The approach could expand the supply of donor lungs and be applied to other donor organs.
Full Text | PDF

Distillery: Therapeutics

Cancer

Top

MicroRNA-29b (miRNA-29b)
doi:10.1038/scibx.2009.1653
A study in cell culture and in mice suggests that miRNA-29b mimetics could help treat AML.
Full Text | PDF

Mdm2 p53 binding protein homolog (MDM2)
doi:10.1038/scibx.2009.1654
In vitro and mouse studies suggest that antagonizing MDM2 could help treat chemotherapy-resistant neuroblastoma.
Full Text | PDF

Integrin α5 (CD49e); radixin (RDX); Ras homolog gene family member (RHOA)
doi:10.1038/scibx.2009.1655
In vitro and mouse studies suggest that inhibiting CD49e, RDX or RHOA could help prevent breast cancer metastasis.
Full Text | PDF

Mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1)
doi:10.1038/scibx.2009.1656
A study in cell culture suggests that inhibiting the protease MALT1 could help treat diffuse large B cell lymphoma.
Full Text | PDF

Microtubules
doi:10.1038/scibx.2009.1657
An in vitro and cell culture study suggests that zampanolide, a macrolide compound isolated from a Tongan sea sponge, could help treat cancer.
Full Text | PDF

Notch transcription factor complex
doi:10.1038/scibx.2009.1658
A study in mice and in cell culture suggests that an α-helical peptide antagonist of the notch transcriptional complex could help treat cancer.
Full Text | PDF

Estrogen receptor
doi:10.1038/scibx.2009.1659
A study in mice suggests that selective estrogen receptor antagonists could help treat and prevent cervical cancer.
Full Text | PDF

Janus kinase 2 (JAK2); histone deacetylase (HDAC)
doi:10.1038/scibx.2009.1660
In vitro studies suggest that combining HDAC inhibitors with JAK2 inhibitors could help treat myeloproliferative cancers.
Full Text | PDF

Wingless-type MMTV integration site family member 5A (WNT5A)
doi:10.1038/scibx.2009.1661
A study in cell culture identified an N-butyloxycarbonyl hexapeptide inhibitor of WNT5A that could help prevent melanoma-associated metastasis.
Full Text | PDF

Cardiovascular disease

Top

Angiotensin-converting enzyme (ACE); endothelin converting enzyme 1 (ECE1); membrane metallo-endopeptidase (MME; NEP; CD10)
doi:10.1038/scibx.2009.1662
In vitro and rat studies suggest that dual ACE and ECE1 inhibitors could help treat hypertension.
Full Text | PDF

Not applicable
doi:10.1038/scibx.2009.1663
In vitro and rat studies suggest that losartan-antioxidant hybrid compounds are more effective than losartan at controlling hypertension.
Full Text | PDF

Dermatology

Top

Androgen receptor
doi:10.1038/scibx.2009.1664
Studies in mice suggest that inhibiting the androgen receptor could improve wound healing.
Full Text | PDF

Hematology

Top

Syntaxin binding protein 2 (STXBP2; MUNC18–2)
doi:10.1038/scibx.2009.1665
Genetic studies in humans identified mutations in STXBP2 that could be biomarkers of the hematological disorder familial hemophagocytic lymphohistiocytosis type 5.
Full Text | PDF

Infectious disease

Top

C-type lectin domain family 7 member A (CLEC7A; DECTIN1)
doi:10.1038/scibx.2009.1666
Genetic studies identified a mutation in DECTIN1 that could help predict susceptibility to recurrent mucocutaneous fungal infections.
Full Text | PDF

HCV NS3 protease
doi:10.1038/scibx.2009.1667
In vitro and rat studies identified macrocyclic HCV NS3 protease inhibitors that could help treat HCV.
Full Text | PDF

Not applicable
doi:10.1038/scibx.2009.1668
In vitro and in vivo studies suggest that a rhodacyanine analog could help treat visceral leishmaniasis.
Full Text | PDF

Histone cluster 4, H4 (HIST4H4)
doi:10.1038/scibx.2009.1669
Studies in cell culture and in mice suggest that blocking HIST4H4 could help treat sepsis.
Full Text | PDF

Solute carrier family 6 member 3 (SLC6A3; DAT1)
doi:10.1038/scibx.2009.1670
Genetic association studies identified two loci that could help predict resistance to TB.
Full Text | PDF

Neurology

Top

Muscarinic acetylcholine receptor M1 (CHRM1; HM1)
doi:10.1038/scibx.2009.1671
In vitro and mouse studies suggest that benzylquinolone carboxylic acid (BQCA) activates HM1 and could help treat cognitive impairment.
Full Text | PDF

NMDA receptor NR2A subtype (GRIN2A; NR2A)
doi:10.1038/scibx.2009.1672
Studies in mice suggest that blocking phosphorylation of NR2A could help treat depression.
Full Text | PDF

Not applicable
doi:10.1038/scibx.2009.1673
Studies in rats suggest that analogs of valproic acid could help treat neuropathic pain and epilepsy.
Full Text | PDF

Adenosine A2A receptor (ADORA2A)
doi:10.1038/scibx.2009.1674
Studies in rats suggest that agonizing ADORA2A could help treat neuropathic pain.
Full Text | PDF

IL-6; IL-6 signal transducer (IL-6ST; gp130; CD130)
doi:10.1038/scibx.2009.1675
Studies in mice suggest that inhibiting gp130 could help treat pain.
Full Text | PDF

Ophthalmic disease

Top

Protein kinase Cδ (PRKCD); Src homology protein tyrosine phosphatase 1 (SHP-1; SHPTP1; PTPN6)
doi:10.1038/scibx.2009.1676
A study in cell culture and in mice suggests that antagonizing PKCD and SHP-1 could help treat diabetic retinopathy.
Full Text | PDF

Pulmonary disease

Top

CD80 (B7–1); cytotoxic T lymphocyte–associated protein 4 (CTLA4; CTLA-4; CD152)
doi:10.1038/scibx.2009.1677
A study in cell culture suggests that antagonizing B7–1 on myeloid dendritic cells (DCs) could help treat inflammation associated with emphysema.
Full Text | PDF

Renal disease

Top

Serum amyloid P component (SAP; APCS)
doi:10.1038/scibx.2009.1678
Studies in mice suggest that SAP could be useful for treating kidney fibrosis.
Full Text | PDF

Distillery: Techniques

Drug platforms

Top

Adoptive therapy to treat autoimmune diseases using engineered antigen-specific Tregs
doi:10.1038/scibx.2009.1679
Adoptive therapy using Tregs engineered to target a specific antigen could help treat autoimmune diseases.
Full Text | PDF

Glycoprotein 2 (GP2)-targeted antigens as mucosal vaccines
doi:10.1038/scibx.2009.1680
GP2-targeted antigen delivery could be useful for developing mucosal vaccines against a variety of pathogens.
Full Text | PDF

IL-10–expressing adult neural stem cells for treatment of autoimmune encephalitis and multiple sclerosis (MS)
doi:10.1038/scibx.2009.1681
Expression of anti-inflammatory IL-10 in adult neural stem cells could improve the ability of implanted cells to treat autoimmune encephalitis and MS.
Full Text | PDF

Imaging

Top

Near-infrared imaging of β-amyloid (Aβ) deposits with curcumin-derived compounds
doi:10.1038/scibx.2009.1682
A curcumin-derived imaging agent could help detect Aβ aggregates to diagnose Alzheimer's disease (AD).
Full Text | PDF

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.

nature publishing group



--
SITBT